Methotrexat Ebewe (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA synthesis. This inhibition reduces the production of nucleotides required for cell replication, particularly affecting rapidly dividing cells such as cancer cells and activated immune cells, thereby exerting both antineoplastic and immunosuppressive effects.

The specific dose of Methotrexat Ebewe is determined by the prescribing healthcare professional based on the patient’s condition, weight, renal function and treatment goals. Dosing regimens vary widely between indications, and the prescriber will tailor the amount and frequency to achieve optimal therapeutic benefit while minimizing risk.

Methotrexat Ebewe is classified as pregnancy category X, meaning it is contraindicated in pregnancy because it can cause fetal harm. Women of child‑bearing potential must use effective contraception. The drug is also excreted in breast milk, so breastfeeding is not recommended while receiving treatment.

To place an order, visit the product page on gnhindia.com, enter the required quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Methotrexate is one of the most widely used antimetabolites, distinguished by its oral availability and broad therapeutic range across oncology and rheumatology. Compared with agents such as 5‑fluorouracil or pemetrexed, methotrexate offers a well‑characterized safety profile and extensive clinical experience, though each drug’s suitability depends on the specific disease and patient factors.

Methotrexat Ebewe should be stored at temperatures below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Methotrexat Ebewe is taken orally as a tablet. The prescriber will specify whether the tablet should be swallowed with water, and whether it should be taken with or without food, based on the individual treatment plan and tolerability considerations.

The most serious risks include severe liver toxicity, pulmonary fibrosis, life‑threatening bone‑marrow suppression, and acute renal failure. Patients should be monitored regularly for liver enzymes, lung function, blood counts and renal parameters to detect early signs of these potentially fatal complications.

Methotrexat Ebewe is contraindicated in pregnant women, individuals with severe hepatic or renal impairment, patients with known hypersensitivity to methotrexate, and those receiving live vaccines. It should also be avoided in patients with uncontrolled infections or severe immunodeficiency unless specifically directed by a specialist.